Clinical trials: Non-Small Cell Carcinoma of Lung, TNM Stage 4
Non-Small Cell Lung Cancer
A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC
The primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of L-DOS47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV…
- Trial name
- NCT02309892
- Testing
- L-DOS47
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Helix BioPharma Corporation
Advanced Lung Non-Small Cell Carcinoma, Non-Small Cell Carcinoma of Lung, TNM Stage 4
A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Metastatic lung cancer is the leading cause of cancer mortality worldwide with a 5-year survival of less than 5%. With the approval of programmed cell death 1 (PD-1) inhibitors in advanced lung cancer, such as pembrolizumab…
- Trial name
- NCT04856176
- Testing
- Granulocyte-Macrophage Colony-Stimulating Factor, Pembrolizumab, pemetrexed
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Tufts Medical Center
Non-Small Cell Carcinoma of Lung, TNM Stage 4
A Real World Study Based on NGS (TRUMPRWS)
This is a descriptive observational study, in which data are collected in an epidemiological fashion. This study does not intend to alter or intervene the current medical practice of the recruited patients.
- Trial name
- TRUMPRWS (NCT03605602)
- Testing
- No treatment is included in this protocol.
- Where
- China
- Volunteers
- 2,700 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-Small Cell Carcinoma of Lung, TNM Stage 4, Radiation Therapy
Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients
study the effect of radiotherapy to the primary lesion after first line systemic therapy in metastatic non-small cell lung cancer patients.
- Trial name
- NCT04776083
- Testing
- first line systemic therapy, 3D radiotherapy or IMRT
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Menoufia University
Non-Small-Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
The optimal prioritization of second-line chemotherapy and immune therapy based on demographic or biomarker data is an area of ongoing investigation.
- Conditions
- Non-Small-Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent
- Trial name
- NCT02967133
- Testing
- Nivolumab, nab-paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance Foundation Trials, LLC.
Non Small Cell Lung Cancer Stage IIIB, Non-Small Cell Carcinoma of Lung, TNM Stage 4
Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)
International multi-center open-label randomized clinical trial of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) monotherapy compared to docetaxel as second-line therapy of patients with advanced…
- Trial name
- DOMINUS (NCT03288870)
- Testing
- BCD-100, Docetaxel
- Where
- 8 sites in Belarus, Russia
- Volunteers
- 218 people
- Sponsor
- Biocad
Non Small Cell Lung Cancer, Non-Small Cell Carcinoma of Lung, TNM Stage 4
Endobronchial Cryotherapy in Management of MEBO in Patients With Inoperable NSCLC
Background: In end-stage patients when all management options have been used, will often develop compromise of their airways as the cancer continues to progress.
- Conditions
- Non Small Cell Lung Cancer, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Bronchogenic Cancer
- Trial name
- NCT04710459
- Testing
- cryotherapy
- Volunteers
- 60 people
- Sponsor
- Mohamed Abdel Bary Ahmed Ibrahim
Triple Negative Breast Cancer, Non-small Cell Lung Cancer
A Biomarker Screening Protocol for Participants With Solid Tumors
Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease…
- Conditions
- Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
- Trial name
- START (NCT05891197)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Lyell Immunopharma, Inc.
Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targeted treatment will allow identification of early adaptive mechanisms…
- Conditions
- Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation
- Trial name
- NCT03042221
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Colorado, Denver
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
Overall survival (OS) of patients with advanced (stage IIIB/IV) non-small-cell lung cancer (NSCLC) remains short after the first line of treatment with a median OS of 12.2 months in non squamous NSCLC and 9.2 months in squamous…
- Conditions
- Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4
- Trial name
- NIRVANA-LUNG (NCT03774732)
- Testing
- Radiotherapy, Pembrolizumab, Chemotherapy
- Where
- 58 sites in France, Monaco
- Volunteers
- 327 people
- Sponsor
- UNICANCER
Non-Small Cell Carcinoma of Lung, TNM Stage 4
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
While cigarette smoking remains the primary cause of most lung cancer cases, lung carcinoma in never smokers account for nearly 20 percent of cases.
- Trial name
- NCT03786692
- Testing
- Arm A, Arm B
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Fox Chase Cancer Center
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
A Study to Investigate LYL797 in Adults With Solid Tumors
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC)…
- Conditions
- Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05274451
- Testing
- LYL797
- Where
- 18 sites in United States
- Volunteers
- 57 people
- Sponsor
- Lyell Immunopharma, Inc.
Non-Small Cell Carcinoma of Lung, TNM Stage 4
Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer
The purpose of this study is to provide high quality oncology services to patients with inoperable Non-Small Cell Lung Cancer (NSCLC) in Greece. These services will be based on 3 pillars: 1.
- Trial name
- SNF-CLIMEDIN (NCT05372081)
- Testing
- Digital platform
- Where
- 15 sites in Greece
- Volunteers
- 200 people
- Sponsor
- Hellenic Cooperative Oncology Group
Non-Small Cell Carcinoma of Lung, TNM Stage 4
Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer
Radiotherapy in combination with different forms of immune therapy improved consistently local tumor control and very interestingly, lead to better systemic tumor control and the induction of specific anti-cancer immunity with a…
- Trial name
- NCT03406468
- Testing
- Radiotherapy
- Where
- 3 sites in Netherlands
- Volunteers
- 36 people
- Sponsor
- Maastricht Radiation Oncology